SHARE

Tarrytown-Based Regeneron To Expand, Add 400 Jobs

TARRYTOWN, N.Y. – Tarrytown-based Regeneron Pharmaceuticals plans to expand its corporate headquarters and laboratories in Westchester County, creating more than 400 new jobs.

Tarrytown-based business Regeneron Pharmaceuticals plans to expand its corporate headquarters and laboratories in Westchester County, creating more than 400 new jobs.

Tarrytown-based business Regeneron Pharmaceuticals plans to expand its corporate headquarters and laboratories in Westchester County, creating more than 400 new jobs.

Photo Credit: Meredith Shamburger

The company and Gov. Andrew Cuomo's office announced the expansion today.

“Our recently approved drugs and our robust development pipeline have transformed Regeneron into one of the largest and fastest-growing biopharmaceutical companies in the United States,” Leonard S. Schleifer, president and chief executive officer, said. “Regeneron has been based in New York since we began 25 years ago, and we are grateful to Gov. Cuomo and New York State for financial support that helps us to continue to expand and create jobs in New York.”

The company plans to add two new buildings at their current site on Old Saw Mill River Road. The 300,000 square-foot office and laboratory space adds to the current 590,000 square-foot building already there and another 85,000 square-feet of additional space to be added later this year.

Regeneron had previously announced it was creating 300 new jobs in Rensselaer through the Excelsior Jobs Program.

“Today’s announcement further advances New York’s reputation as a leader in the biotech industry,” Cuomo said. “This administration has had a laser-like focus on creating an environment where companies, such as Regeneron, can grow and invest. The expansion of Regeneron’s headquarters and the addition of hundreds of new high-skill jobs is great news for Westchester County and great news for New York.”

to follow Daily Voice Tarrytown-SleepyHollow and receive free news updates.

SCROLL TO NEXT ARTICLE